Results 1 to 10 of about 19,627 (213)
Prevalence of Nitroimidazole-Refractory Giardiasis Acquired in Different World Regions, Sweden, 2008–2020 [PDF]
Emerging Infectious DiseasesTreatment-refractory giardiasis is an emerging clinical problem. Of 4,285 giardiasis cases identified during 2008–2020 in Stockholm, Sweden, 102 (2.4%) were nitroimidazole refractory. Among cases acquired in India, the percentage was high (64/545 [12%])
Karin A. Ydsten +3 more
doaj +2 more sources
Exploring CPP Enhanced Hypoxia Targeting: An Approach Using Radiolabeled 2-nitroimidazole TAT Conjugate. [PDF]
Drug Dev ResABSTRACT Mediated by their protein transduction domain, cell‐penetrating peptides (CPPs) have been widely explored for facilitating intracellular delivery of drugs and small molecules. In this study, a radiolabeled, 2‐nitroimidazole conjugated TAT (TAT ‐ transactivator of transcription) peptide was prepared and evaluated for targeting tumor hypoxia ...
Mittal S +4 more
europepmc +2 more sources
Pharmaceuticals, 2022 Nitroimidazole represents one of the most essential and unique scaffolds in drug discovery since its discovery in the 1950s. It was K. Maeda in Japan who reported in 1953 the first nitroimidazole as a natural product from Nocardia mesenterica with ...
Ria Gupta +5 more
doaj +1 more source
Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers
Molecules, 2023 The role of hypoxic tumour cells in resistance to radiotherapy, and in suppression of immune response, continues to endorse tumour hypoxia as a bona fide, yet largely untapped, drug target.
Lydia P. Liew +6 more
doaj +1 more source
Antioxidants, 2023 Cellular adaptations to hypoxia promote resistance to ionizing radiation (IR). This presents a challenge for treatment of head and neck cancer (HNC) that relies heavily on radiotherapy.
Faisal Bin Rashed +5 more
doaj +1 more source
Molecules, 2022 Nitro-containing compounds are a well-known class of anti-infective agents, especially in the field of anti-parasitic drug discovery. HAT or sleeping sickness is a neglected tropical disease caused by a protozoan parasite, Trypanosoma brucei.
Alireza Mousavi +5 more
doaj +1 more source
Niclosamide Is Active In Vitro against Mycetoma Pathogens
Molecules, 2021 Redox-active drugs are the mainstay of parasite chemotherapy. To assess their repurposing potential for eumycetoma, we have tested a set of nitroheterocycles and peroxides in vitro against two isolates of Madurella mycetomatis, the main causative agent ...
Abdelhalim B. Mahmoud +5 more
doaj +1 more source
Periodontology 2000, EarlyView., 2023 Abstract This narrative review celebrates Europe's contribution to the current knowledge on systemically administered antimicrobials in periodontal treatment. Periodontitis is the most frequent chronic noncommunicable human disease. It is caused by dysbiotic bacterial biofilms and is commonly treated with subgingival instrumentation.
David Herrera +4 more
wiley +1 more source
Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership
Diseases, 2022 After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre ...
Sonja Bernhard +3 more
doaj +1 more source
Supra and subgingival application of antiseptics or antibiotics during periodontal therapy
Periodontology 2000, EarlyView., 2023 Abstract Periodontal diseases (gingivitis and periodontitis) are characterized by inflammatory processes which arise as a result of disruption of the balance in the oral ecosystem. According to the current S3 level clinical practice guidelines, therapy of patients with periodontitis involves a stepwise approach that includes the control of the patient ...
Elena Figuero +5 more
wiley +1 more source